Corporate Crime in the Pharmaceutical Industry (Routledge Revivals)First published in 1984, this book examines corporate crime in the pharmaceutical industry. Based on extensive research, including interviews with 131 senior executives of pharmaceutical companies in the United States, the United Kingdom, Australia, Mexico and Guatemala, the book is a major study of white-collar crime. Written in the 1980s, it covers topics such as international bribery and corruption, fraud in the testing of drugs and criminal negligence in the unsafe manufacturing of drugs. The author considers the implications of his findings for a range of strategies to control corporate crime, nationally and internationally. |
Contents
| 1 | |
| 11 | |
from negligence to fraud | 51 |
4 Unsafe manufacturing practices | 110 |
5 Antitrust | 159 |
6 The corporation as pusher | 204 |
7 Drug companies and the Third World | 245 |
8 Fiddling | 279 |
9 Strategies for controlling corporate crime | 290 |
Appendix Getting interviews with corporate executives | 384 |
Notes | 389 |
| 408 | |
| 428 | |
Other editions - View all
Corporate Crime in the Pharmaceutical Industry (Routledge Revivals) John Braithwaite Limited preview - 2013 |
Corporate Crime in the Pharmaceutical Industry (Routledge Revivals) John Braithwaite No preview available - 2014 |
Common terms and phrases
adverse advertising alleged American antibiotics antitrust approval argued Australian bribery bribes cent ceutical Chapter chief executive officer chloramphenicol claims clinical clioquinol com company’s compliance group con consumer cor Cordis corporate crime corrupt costs countries court criminal Cyanamid decision developed doctors drug companies economic effective employees firms fraud Griinenthal Guatemala headquarters Hoffman-La Roche Hospital important imposed individual inspection inspectors interest interviews investigation laboratory liability manufacturing Medtronic ment Merck million offenders oligopoly organisation pacemakers Parke-Davis patients Pfizer pharma pharmaceutical companies pharmaceutical industry physicians plant prescription pro problem profits promotion prosecution protection quality control manager questionable payments regulation regulatory agencies responsibility Richardson-Merrell risk Roche safety sales representatives sanctions Searle Senate senior side-effects Silverman Squibb standards Subcommittee on Health subsidiary Syntex testing tetracycline thalidomide Third World tion transfer prices Transnational Corporations United Valium violations